Literature DB >> 32351649

Morbidity and mortality risk factors in emergency department patients with Acinetobacter baumannii bacteremia.

Rui-Xue Sun1, Priscilla Song2, Joseph Walline3, He Wang4, Ying-Chun Xu4, Hua-Dong Zhu1, Xue-Zhong Yu1, Jun Xu1.   

Abstract

BACKGROUND: Acinetobacter baumannii (AB) bacteremia is an increasingly common and often fatal nosocomial infection. Identification of morbidity and mortality risk factors for AB bacteremia in emergency department (ED) patients may provide ways to improve the clinical outcomes of these patients.
METHODS: The records for 51 patients with AB bacteremia and 51 patients without AB infection were collected and matched in a retrospective case-control study between 2013 and 2015 in a single-center ED. Risk factors were analyzed by Chi-square and multivariate logistic regression statistical models.
RESULTS: A significant risk factor for morbidity was the presence of a central venous catheter (CVC) (P<0.001). The mortality rate for the 51 patients with AB bacteremia was 68.6%. Risk factors for mortality were the presence of a CVC (P=0.021) and an ED stay longer than two weeks (P=0.015).
CONCLUSION: AB infections lead to high morbidity and mortality. The presence of a CVC was associated with higher morbidity and mortality in patients with AB bacteremia. Avoiding CVC insertions may improve outcomes in ED patients with AB bacteremia. Copyright: © World Journal of Emergency Medicine.

Entities:  

Keywords:  Acinetobacter baumannii; Bacteremia; Morbidity; Mortality

Year:  2020        PMID: 32351649      PMCID: PMC7183915          DOI: 10.5847/wjem.j.1920-8642.2020.03.006

Source DB:  PubMed          Journal:  World J Emerg Med        ISSN: 1920-8642


  27 in total

1.  Obstructive shock secondary to fungal prosthetic aortic valve endocarditis.

Authors:  Emilio Rodriguez-Ruiz; Diego Iglesias-Alvarez; Carlos Peña-Gil
Journal:  World J Emerg Med       Date:  2018

2.  Clinical effectiveness and risk of emerging resistance associated with prolonged use of antibiotic-impregnated catheters: more than 0.5 million catheter days and 7 years of clinical experience.

Authors:  Elizabeth R Ramos; Ruth Reitzel; Ying Jiang; Ray Y Hachem; Ann Marie Chaftari; Roy F Chemaly; Brenda Hackett; S Egbert Pravinkumar; Joseph Nates; Jeffrey J Tarrand; Issam I Raad
Journal:  Crit Care Med       Date:  2011-02       Impact factor: 7.598

3.  A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia.

Authors:  Tat Ming Ng; Christine B Teng; David C Lye; Anucha Apisarnthanarak
Journal:  Infect Control Hosp Epidemiol       Date:  2013-11-26       Impact factor: 3.254

4.  Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant acinetobacter baumannii.

Authors:  Tugba Arslan Gulen; Rahmet Guner; Nevreste Celikbilek; Siran Keske; Mehmet Tasyaran
Journal:  Int J Infect Dis       Date:  2015-06-28       Impact factor: 3.623

5.  Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.

Authors:  Chang-Pan Liu; Shou-Chuan Shih; Nai-Yu Wang; Alice Y Wu; Fang-Ju Sun; Shan-Fan Chow; Te-Li Chen; Tsong-Rong Yan
Journal:  J Microbiol Immunol Infect       Date:  2014-11-11       Impact factor: 4.399

6.  Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.

Authors:  C Routsi; M Pratikaki; E Platsouka; C Sotiropoulou; S Nanas; V Markaki; C Vrettou; O Paniara; H Giamarellou; C Roussos
Journal:  Infection       Date:  2010-03-12       Impact factor: 3.553

7.  Effectiveness of Minocycline and Rifampin vs Chlorhexidine and Silver Sulfadiazine-Impregnated Central Venous Catheters in Preventing Central Line-Associated Bloodstream Infection in a High-Volume Academic Intensive Care Unit: A Before and after Trial.

Authors:  Stephanie Bonne; John E Mazuski; Carie Sona; Marilyn Schallom; Walter Boyle; Timothy G Buchman; Grant V Bochicchio; Craig M Coopersmith; Douglas J E Schuerer
Journal:  J Am Coll Surg       Date:  2015-05-27       Impact factor: 6.113

Review 8.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 9.  Current control and treatment of multidrug-resistant Acinetobacter baumannii infections.

Authors:  Drosos E Karageorgopoulos; Matthew E Falagas
Journal:  Lancet Infect Dis       Date:  2008-12       Impact factor: 25.071

10.  Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy.

Authors:  Youn Jeong Kim; Sang Il Kim; Kyung-Wook Hong; Yang Ree Kim; Yeon Joon Park; Moon-Won Kang
Journal:  J Korean Med Sci       Date:  2012-04-25       Impact factor: 2.153

View more
  2 in total

1.  Molecular Epidemiology and Clone Transmission of Carbapenem-Resistant Acinetobacter baumannii in ICU Rooms.

Authors:  Xiufeng Zhang; Fangping Li; Furqan Awan; Hongye Jiang; Zhenling Zeng; Weibiao Lv
Journal:  Front Cell Infect Microbiol       Date:  2021-02-26       Impact factor: 5.293

2.  Impact of target site mutations and plasmid associated resistance genes acquisition on resistance of Acinetobacter baumannii to fluoroquinolones.

Authors:  Mostafa Ahmed Mohammed; Mohammed T A Salim; Bahaa E Anwer; Khaled M Aboshanab; Mohammad M Aboulwafa
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.